Powder: -20℃ for 3 years. In solvent: -80℃ for 1 year.
Description
HRX-0233 is a small molecule inhibitor targeting MAP2K4. In vivo, HRX-0233 effectively reduces tumors in H358 KRASG12C mutant non-small cell lung cancer (NSCLC) without significant toxicity.